2022
December 8, 2022
Vertex and Entrada Therapeutics Establish Collaboration to Discover and Develop Endosomal Escape Vehicle (EEV) Therapeutics for Myotonic Dystrophy Type 1 (DM1)
September 9, 2022
Photys Therapeutics Debuts with $75 Million Series A Funding to Advance New Class of Bifunctional Molecules for Precision Phosphorylation to Modulate and Repair Disease-Driving Proteins
August 31, 2022
Umoja’s Unified Approach to Exceeding the Limitations of Cell Therapy
August 25, 2022
AKTIS ONCOLOGY RAISES $84 MILLION TO ADVANCE NOVEL TARGETED ALPHA RADIOPHARMACEUTICALS
August 18, 2022
Orna goes into orbit on $3.65B Merck megadeal, $221M series B round
August 18, 2022
Orna Therapeutics: circular logic
August 16, 2022
BioImpact Capital, an MPM affiliate, Announces a Multi-Billion Dollar Landmark Transaction in Vaccines and Cancer
August 16, 2022
Merck and Orna Therapeutics Collaborate to Advance Orna’s Next Generation of RNA Technology
August 16, 2022
Orna Therapeutics Raises $221 Million Series B Financing to Advance Circular RNA Platform and Accelerate Programs to the Clinic
June 2, 2022
Chris Bardon Interview (GBR Capital)
June 2, 2022
Repare Therapeutics Announces a Worldwide License and Collaboration Agreement with Roche for Camonsertib (RP-3500)
May 12, 2022
Cullinan Oncology and Taiho Pharmaceutical Announce Strategic Collaboration to Jointly Develop and Commercialize CLN-081/TAS6417 and Taiho’s Acquisition of Cullinan Pearl
March 8, 2022
AACR and MPM Oncology Charitable Foundation Announce Two Grants to Support Transformative Cancer Research
March 5, 2022
Harpoon Therapeutics Receives FDA Fast Track Designation for HPN217
January 6, 2022
Top Life Sciences Startups to Watch in 2022
January 6, 2022
FDA Grants Breakthrough Therapy Designation for Cullinan Oncology’s CLN-081 in Patients with Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer
2021
December 16, 2021
Cullinan Oncology Announces Updated Phase 1/2a Data for CLN-081 in NSCLC EGFR Exon 20 Patients
December 7, 2021
MPM Capital Announces the Addition of Detlev Biniszkiewicz, Ph.D. to its Investment Committee
November 17, 2021
Protego Biopharma Raises $51 Million Series A Financing to Advance the Treatment of Protein Misfolding Diseases
October 29, 2021
Entrada Therapeutics Announces Pricing of Upsized Initial Public Offering
October 22, 2021
ReCode Therapeutics Raises Oversubscribed Series B Financing Round of $80 Million
October 19, 2021
Future Returns: MPM Capital’s Second Oncology Impact Fund Goes Beyond Cancer
October 18, 2021
A single patient is producing insulin after treatment with Vertex’s new diabetes cell therapy
October 18, 2021
MPM Advisor Bill Hahn elected to the National Academy of Medicine
October 11, 2021
Listen to Thomas Barnes, Chief Executive Officer of MPM Company ORNA, on Pioneering circular oRNA therapeutics
October 6, 2021
MPM Capital Raises Biotech’s Largest Impact Investment Fund to Help Finance the Fight Against Cancer and Other Diseases
October 1, 2021
The Next RNA Breakthrough? Maybe Bending Strands Into Circles
September 30, 2021
MPM’s Chris Bardon Speaks on CNBC’s Delivering Alpha
September 23, 2021
MPM Strengthens its Team with the Addition of Accomplished Biotech Executive and Drug Discoverer Wendy Young, PhD
September 21, 2021
MPM Expands its Team with the Appointment of RNA Expert and Leading Biotech Executive Pete Smith, PhD
August 30, 2021
From bench to boardroom: 20 of the most influential biopharma R&D executives in drug development
July 8, 2021
Burrage Capital Joins Forces With MPM
June 21, 2021
Umoja Biopharma Closes an Oversubscribed $210 Million Series B Financing to Expand Integrated Immunotherapy Platforms and Advance Programs to the Clinic
June 14, 2021
GSK pays iTeos $625M upfront to join Merck, Roche and the rest in TIGIT immuno-oncology race
June 14, 2021
iTeos Therapeutics and GSK announce development and commercialisation collaboration for EOS-448, an anti-TIGIT monoclonal antibody, enabling novel next-generation immuno-oncology combinations
June 4, 2021
iTeos Therapeutics Announces New Phase 1/2a Data Indicating Antitumor Activity of inupadenant, its Adenosine A2A Receptor Antagonist, at ASCO 2021
May 25, 2021
These are the 2021 CNBC Disruptor 50 companies
May 7, 2021
Chiasma Reports First Quarter Financial Results and Announced Agreement to Merge with Amryt
May 3, 2021
Werewolf Therapeutics Announces Pricing of Upsized Initial Public Offering
April 13, 2021
Pankaj Bhargava was a central figure in the group fashioning Gilead’s oncology strategy. Now he’s jumped to the VC side and the next-gen game at Dana-Farber
April 13, 2021
MPM Capital Adds to Senior Team with the Appointment of Oncology Leader Pankaj Bhargava, MD as Executive Partner
March 31, 2021
Entrada Therapeutics Announces Closing of $116 Million Series B Financing
March 18, 2021
Aktis Oncology Announces $72M Series A Financing To Advance Breakthrough Radiopharmaceuticals To Treat Solid Tumors
March 18, 2021
Are radiopharmaceuticals ready for the mainstream? Novartis, Bristol Myers Squibb bet yes on MPM’s platform take
March 15, 2021
ElevateBio Scales Disruptive Cell and Gene Therapy Business Model with $525 Million Series C Financing
March 11, 2021
Future Returns: How UBS Surpassed a $5 Billion Impact Goal
March 9, 2021
Takeda to Acquire Maverick Therapeutics
February 24, 2021
Orna Therapeutics Launches with over $100M Raised to Develop a New Class of Fully Engineered Circular RNA Therapies
February 24, 2021
The mRNA era is here. MPM believes the future belongs to oRNA- and Big Pharma wants a seat at the table
January 20, 2021
TCR² Therapeutics Announces Pricing of Public Offering of $140.0 Million of Common Stock
January 19, 2021
AACR and MPM Oncology Charitable Foundation Announce Three Grants to Support Transformative Cancer Research
January 8, 2021
Cullinan Management Announces Pricing of Upsized Initial Public Offering (CORRECTION)
January 7, 2021
Werewolf Therapeutics Completes $72 Million Series B Financing
January 5, 2021
MPM Capital Announces the Promotions of Shinichiro Fuse, Ph.D. and Kristen Laguerre to its Investment Committee
2020
December 18, 2020
Cullinan Oncology Completes $131.2 Million Series C Financing
December 13, 2020
TCR² ANNOUNCES RECIST RESPONSE IN OVARIAN CANCER FROM ONGOING PHASE 1/2 TRIAL
December 8, 2020
Harpoon Therapeutics Reports Clinical Progress Across All Four TriTAC® Pipeline Development Programs
November 30, 2020
Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE™
November 19, 2020
Umoja Biopharma Raises $53M in Series A Financing
October 2, 2020
ONCORUS ANNOUNCES PRICING OF INITIAL PUBLIC OFFERING
September 29, 2020
MPM joins the historic SPAC boom as its blank check company files for an IPO
September 18, 2020
Roden, fresh from BMS-Celgene merger, lands VC role at MPM
September 17, 2020
MPM Capital Bolsters Senior Team with Appointment of Matthew Roden as Executive Partner
September 17, 2020
After leading Celgene buyout, Matthew Roden leaves Bristol Myers Squibb for venture capital firm
September 16, 2020
Dyne Therapeutics Announces Pricing of Initial Public Offering
August 11, 2020
DYNE THERAPEUTICS ANNOUNCES $115 MILLION FINANCING TO ADVANCE PIPELINE OF MODERN OLIGONUCLEOTIDE THERAPEUTICS FOR SERIOUS MUSCLE DISEASES
July 30, 2020
AlloVir Announces Pricing of Upsized Initial Public Offering
July 28, 2020
TCR² THERAPEUTICS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK
July 24, 2020
iTeos Therapeutics Announces Pricing of Initial Public Offering
July 21, 2020
Gilead Sciences Secures Exclusive Option to Acquire Tizona Therapeutics for $300 Million
July 16, 2020
Oncorus Announces Clinical Trial Collaboration with Merck
June 27, 2020
Chiasma Announces FDA Approval of MYCAPSSA® (Octreotide) Capsules, the First and Only Oral Somatostatin Analog
June 23, 2020
Repare Therapeutics Announces Pricing of Upsized Initial Public Offering
June 6, 2020
Cullinan Oncology Completes $98.5 Million Series B Financing
June 1, 2020
After Inking Bristol Myers Pact, Repare Therapeutics Sets Sights on IPO
May 28, 2020
Repare Therapeutics Announces Multi-Target Discovery Collaboration with Bristol Myers Squibb
April 1, 2020
iTeos Therapeutics Closes $125 Million Series B2 Financing
March 31, 2020
ElevateBio Closes $170 Million Series B Financing
March 30, 2020
ReCode Therapeutics Raises $80 Million In Oversubscribed Series A Financing
February 26, 2020
MPM Capital Announces $100M Oncology Innovations Fund as Part of Novel Venture Philanthropy Collaboration with Dana-Farber Cancer Institute
February 26, 2020
WSJ.com – MPM Capital Raises $100 Million Fund, Teams Up With Dana-Farber Cancer Institute
February 26, 2020
FierceBiotech – MPM gains first offer on Dana-Farber tech, raises $100M fund
February 26, 2020
Endpoints News – Tying basic science to spinouts, Dana-Farber debuts sister funds totaling $126M with MPM Capital
February 24, 2020
AACR to Receive $2 Million to Support Innovative Research from UBS Oncology Impact Fund Managed by MPM Capital
February 12, 2020
AlloVir Receives the European Medicines Agency PRIME Designation for Viralym-M, an Allogeneic, Off-the-Shelf, Multi-Virus Specific T-Cell Therapy
February 7, 2020
Dyne Therapeutics Expands Leadership Team with Key Hires
February 5, 2020
CODA Biotherapeutics Acquires Attenua and Three Clinical Stage Assets
January 30, 2020
iTeos Therapeutics Awarded €15 Million in Non-Dilutive Funding by the Walloon Region
January 23, 2020
Epizyme Receives FDA Accelerated Approval of TAZVERIK™ (tazemetostat) for the Treatment of Epithelioid Sarcoma
January 6, 2020
BioIntervene Announces $30 Million Series A Financing
2019
December 17, 2019
The AACR-MPM Oncology Charitable Foundation Announces First Grants to Support Transformative Cancer Research
December 17, 2019
Triplet Therapeutics Launches with $59 Million in Financing to Further Its Development of Transformative Treatments for Triplet Repeat Disorders
November 21, 2019
Harpoon Therapeutics and AbbVie Announce Licensing and Option Collaboration to Advance HPN217, Harpoons’ BCMA-Targeting TriTAC®, and Expand Existing Discovery Collaboration
Overall Deal Potential Valued up to $2.4B
November 20, 2019
Werewolf Therapeutics Launches with $56M Series A Financing to Develop Transformative Immuno-Stimulatory Cancer Medicines
November 18, 2019
Novartis and MPM Capital Invest in SiO2 Medical Products Developing a Potentially Disruptive Novel Packaging Technology
November 15, 2019
New Novartis Medicine Adakveo® (crizanlizumab) Approved by FDA to Reduce Frequency of Pain Crises in Individuals Living with Sickle Cell Disease
Therapy developed by MPM portfolio company Selexys, acquired by Novartis in 2016
November 5, 2019
CODA Biotherapeutics Announces Series A Extension, Bringing Total Round to $34M
October 16, 2019
Rhythm Pharmaceuticals, Inc. Announces Pricing of Public Offering
October 8, 2019
MPM’s Todd Foley Comments on Pharma Market in WSJ Pro VC “Pharma Mergers, Strong IPO Market Mute Startup Acquisitions”
October 7, 2019
TriNetX Named Technology Partner for FDA Sentinel System
September 25, 2019
Blade Therapeutics Expands Anti-Fibrotic Pipeline With Acquisition of ATXCo
September 24, 2019
MPM Capital Executive Partner Patrick Baeuerle Wins 2019 Xconomy “X of the Year” Award
September 24, 2019
Amphivena Closes $62 Million Series C Financing to Expand the Clinical Development of AMV564 into Solid Tumors and to Develop its T Cell Engagement Portfolio
September 23, 2019
MPM Capital Portfolio Company Frontier Medicines Honored with a Fierce 15 Award
September 4, 2019
MPM’s Todd Foley Discusses Acquisition of Semma Therapeutics in WSJ Pro VC “Vertex Makes Another Aggressive Purchase With Semma”
September 4, 2019
Repare Therapeutics Announces US$82.5 Million Series B Financing
September 3, 2019
Semma Therapeutics to be Acquired by Vertex for $950M
August 22, 2019
Iconic Therapeutics Signs Ophthalmology Option Agreement with Novartis
August 21, 2019
Oncorus Announces $79.5 Million Series B Financing to Support the Advancement of Oncolytic Virus Therapies to Transform Outcomes for Cancer Patients
July 26, 2019
Chiasma Announces Pricing Of Underwritten Public Offering Of $55.0 Million Of Common Stock
July 26, 2019
MGH and ElevateBio Announce a 10-Year Alliance Agreement to Utilize ElevateBio BaseCamp to Manufacture Innovative Cell and Gene Therapies
June 25, 2019
Frontier Medicines Launches with $67M Series A Financing
Developing novel medicines that drug previously considered “undruggable” targets, starting with cancer
May 22, 2019
Portfolio Company ElevateBio Announces that Allovir Joins its Portfolio of Highly Innovative Cell and Gene Therapy Companies
May 16, 2019
Iconic Therapeutics And Exelixis Enter into Exclusive Option and License Agreement for Novel Antibody-drug Conjugate Program
May 13, 2019
ElevateBio Launches to Create and Operate a Portfolio of Highly Innovative Cell and Gene Therapy Companies
$150M Series A financing co-led by UBS Oncology Impact Fund Managed by MPM Capital
April 26, 2019
Aratana Therapeutics to be Acquired by Elanco Animal Health
April 3, 2019
AACR-MPM Oncology Charitable Foundation Transformative Cancer Research Grants Program Now Inviting Applications
April 3, 2019
Dyne Therapeutics Launches with $50 Million Series A to Develop Targeted Therapies for Muscle Diseases
March 13, 2019
TriNetX Secures $40 Million in Series D Funding
February 22, 2019
MPM’s Patrick A. Baeuerle Awarded the 2019 Lennart Philipson Award for Contributions to Cancer Immunotherapy
February 22, 2019
BioCentury: MPM Keeps Building
Luke Evnin speaks with Chris Lieu at BioCentury (full article - subscription)
February 21, 2019
The Wall Street Journal: Biotech Investor MPM Capital Refuels With $400 Million Venture Fund
Ansbert Gadicke speaks with Brian Gormley at the Wall Street Journal (full article -subscription)
February 21, 2019
Scrip Pharma intelligence: MPM Raises $400M To Build Early-Stage Biotechs
Ansbert Gadicke speaks with Kevin Grogan at Scrip Pharma intelligence (full article -subscription)
February 21, 2019
Endpoints News: MPM Adds $408M for its Next Big Wave of Biotech Startups — and Oncology Still Dominates the Menu
Luke Evnin speaks with John Carroll at Endpoints News
February 21, 2019
MPM Capital Raises $400 Million to Fund Early-Stage Biotech Innovation
February 20, 2019
Harvard Business Review: Impact Investing Could Accelerate the Fight Against
UBS Oncology Impact Fund managed by MPM cited as a “..model other funds could emulate..”
January 3, 2019
Tizona Therapeutics Appoints Scott Clarke as Chief Executive Officer and Provides Update on Regulatory Milestone for its First-in-Class CD39 program in Cancer
January 3, 2019
Tizona Therapeutics and AbbVie Announce Strategic Collaboration to Develop First-in-Class Immunotherapy for Cancer Targeting CD39
2018
December 18, 2018
Entrada Therapeutics Raises $59 Million Series A to Advance Intracellular Biologics Platform
Series A co-led by 5AM Ventures and MPM Capital, along with other top investors
November 29, 2018
TCR2 Therapeutics wins U.S. Private Company of the Year Award at LifeStars Awards™ Life Sciences 2018 Event
November 12, 2018
Harpoon Therapeutics Announces Closing of $70M Series C Financing
September 25, 2018
Verastem Oncology Receives FDA Approval of COPIKTRA™ (duvelisib) Capsules
Treatment for adult patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) after at least two prior therapies
September 13, 2018
MPM Capital Expands its Team of Executive Partners and Entrepreneurs with the Appointments of Biotech Leaders Detlev Biniszkiewicz and Scott Chappel
September 12, 2018
MPM Capital and Versant Ventures Launch CODA Biotherapeutics to Accelerate Development of Chemogenetic Gene Therapy Platform
Industry veteran Michael Narachi joins as President and CEO
September 6, 2018
Twentyeight-Seven Therapeutics Launches with a $65 Million Series A Funding
August 6, 2018
Harpoon Therapeutics Treats First Patient With HPN424 in Phase 1 Clinical Trial of Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients
HPN424, First-in-Class TriTAC™ T Cell Redirection Therapy, Targets Prostate-Specific Membrane Antigen (PSMA)
August 1, 2018
Oncorus®, Inc., Names Industry Veteran Ted Ashburn as new President and CEO
– Company co-founder Mitch Finer named new Chairman of the Board –
July 18, 2018
Maverick Therapeutics Advances Technology; Adds Key Management
James R. Vasselli MD to Lead Clinical Development
June 27, 2018
MPM Executive Partner, David Hallal, Appointed Chairman of iTeos Therapeutics
June 26, 2018
Patrick Baeuerle, MPM Executive Partner and Immunotherapy Pioneer, to Present Compelling Data from Harpoon Therapeutics’ Biotherapeutics Platform at the 2018 European Congress on Biotechnology
June 20, 2018
MPM Leads $75 Million Series B Financing of iTeos Therapeutics
May 29, 2018
Chris Bardon Talks to WSJ Pro VC about Late-Stage Combination Therapy Trials
May 22, 2018
MPM Cancer Research Partnership with AACR Featured in Medpage Today
AACR Ventures into New Cancer Research Funding Model—Adapting model pioneered by Cystic Fibrosis Foundation
May 10, 2018
MPM Portfolio Company Semma Therapeutics Appoints Bastiano Sanna, Ph.D. as CEO and President
May 5, 2018
Chris Bardon Comments to Reuters on the OIF and its Philanthropic Impact
Read: “Executive Perspective: An example of innovative impact investing from UBS”
May 2, 2018
Watch Now: Chris Bardon is a Featured Panelist at Paying for Cures – Global Conference 2018 | Milken Institute
April 23, 2018
MPM’s Approach to Investing is Positively Impacting Cancer Research and Care
Learn more in BioWorld article, “Socially Conscious Investing Benefits AACR, UBS’ Optimus”
April 19, 2018
MPM’s Partnership with AACR Highlighted in WSJ Pro VC “Gormley’s Take: Health-Care Investors Doing Good After Doing Well”
April 18, 2018
MPM Capital Portfolio Company Tetherex Pharmaceuticals Completes $50M Series B Financing
April 16, 2018
MPM and AACR Announce Partnership in Cancer Research
April 16, 2018
Watch Now: Press Event Announcing MPM and AACR Partnership in Cancer Research
Panel from AACR, MPM and UBS Discuss First Funding Gift from UBS Oncology Impact Fund managed by MPM
April 16, 2018
MPM and AACR Partnership Featured in Barron’s Article “UBS Oncology Impact Fund Announces $2.5M in Gifts”
April 15, 2018
Watch Now: Chris Bardon Announces MPM and AACR Partnership in Cancer Research at AACR 2018 Opening Ceremony
April 9, 2018
MPM’s Chris Bardon Comments on Lessons Learned from Recent IO Trial Results
Read BioWorld article “Epacadostat/Keytruda Pivotal Trial Flop Sends Shivers Down IDO Pathway”
March 21, 2018
MPM Portfolio Company TCR2 Therapeutics Raises $125 Million in Oversubscribed Series B Financing
February 20, 2018
Cullinan Oncology and MAB Discovery Announce Collaboration to Develop Novel Antibody-Based Therapeutics
January 24, 2018
Astellas Completes Acquisition of Mitobridge, Inc.
January 11, 2018
BioWorld’s Key Highlights from the Women in Bio and Bloomberg Intelligence Panel with Chris Bardon at JPM18
“Women Have Their Say as All-Female Panel Talks Biopharma Investment, Technology Trends”
January 10, 2018
Syndax Pharmaceuticals Announces Clinical Collaboration to Evaluate Entinostat in Combination with anti-PD-L1 Cancer Immunotherapy in Breast Cancer
January 9, 2018
WATCH NOW: Chris Bardon Discusses the Cycle of Innovation and Value of Transformative Therapies on CNBC
January 9, 2018
Rhythm Pharmaceuticals Enters into Partnership with WuXi NextCODE the Emerging Global Standard Platform for Genomic Data
The partnership will help Rhythm identify genetic markers for rare metabolic syndromes and optimize investigational compounds
January 8, 2018
Chris Bardon Shares her Thoughts on Market Trends and Innovative Therapies with BioWorld
“‘Spirit’ of JPM Lives on as Other Meetings Muscle in on Biopharma Playground”
January 3, 2018
TCR2 Therapeutics to Present at the 36th Annual J.P. Morgan Healthcare Conference
2017
December 9, 2017
Chris Bardon Comments on Positive Gene Therapy Data in Forbes article, “Excitement Builds Around Gene Therapy Cures For Hemophilia”
December 1, 2017
MPM portfolio company, Mitobridge, Inc. to be acquired by Astellas Pharmaceuticals in a deal worth up to $450 million
November 30, 2017
Semma Therapeutics Raises $114m for Novel Diabetes Treatment
October 19, 2017
Syndax Expands Pipeline with Exclusive Worldwide License to Allergan’s Portfolio of Menin-MLL Inhibitors
October 19, 2017
TCR2 Therapeutics Appoints Leading Cell Therapy Expert as Chief Medical Officer
October 19, 2017
Blade Therapeutics Announces Selection of a Clinical Development Candidate and Funding of the Second Tranche for its Series B Financing
October 18, 2017
AbbVie and Harpoon Therapeutics Announce Immuno-Oncology Research Collaboration
October 17, 2017
Mitobridge featured in Bloomberg article, “One Scientist’s Marathon Quest for the Exercise Pill”
October 4, 2017
Rhythm Pharmaceuticals, Inc. Announces Pricing of Initial Public Offering
October 3, 2017
Oncorus®, Inc., Names Christophe Quéva, Ph.D., as Chief Scientific Officer
October 3, 2017
The UBS Oncology Impact Fund Co-leads $150 Million Series A Financing of Cullinan Oncology
Cullinan Oncology is an Innovative Development Company with an Accomplished Management Team to Develop Pipeline of Novel Cancer Therapies
September 26, 2017
Repare Therapeutics Named as One of FierceBiotech’s “Fierce 15” Biotech Companies of 2017
September 16, 2017
Inside Perspectives on Gene Editing: An Interview with MPM Capital’s Mitchell Finer
September 15, 2017
TCR2 Therapeutics Named One of the 15 Innovative Immuno-Oncology Biotechs to Watch in 2018 by Immuno-Oncology Frontiers
September 13, 2017
Oncorus’ Viral Cancer Vaccine Highlighted in WSJ: “Scientists See Progress for Cancer Vaccines”
September 5, 2017
Inside Perspectives on Cancer Immunotherapy: An Interview with MPM’s Christiana Bardon
September 1, 2017
Gormley’s Take: Writing War on Cancer’s Next Chapter –– Biotech startups seek to widen benefits of revolutionary cell-therapy treatments
WSJ Pro Venture Capital features MPM’s Chris Bardon and TCR2
August 31, 2017
MPM’s Chris Bardon Applauds Novartis’ Value-Based Pricing Move for its CAR-T Cell Therapy Kymriah
Read BioWorld article “Gene therapy, cloaked in cell therapy, arrives in U.S. courtesy of Kymriah”
August 11, 2017
Maverick Therapeutics Appoints James S. Scibetta as CEO
July 27, 2017
MPM’s Chris Bardon Talks to BioWorld About Recent Pharma R&D Restructuring
Trends point to pharma focus on signing more early stage partnerships
July 17, 2017
Radius Health Appoints Jesper Høiland as President and Chief Executive Officer
Leading the Next Stage Of Growth and Value Creation As A Fully Integrated Commercial Biotech Company
June 28, 2017
Semma Therapeutics Mentioned in WSJ article “Biotech Startups’ Cell-Based Diabetes Attack”
June 22, 2017
MPM and Versant Venture Co-Lead Series A Financing of Repare Therapeutics
June 21, 2017
Proteon Therapeutics Announces $22.0 Million Private Placement
June 20, 2017
Visionary Scientist Stephen J. Elledge Joins MPM Capital’s Medical and Scientific Advisory Board
June 13, 2017
Accomplished Oncologist and Scientist William C. Hahn Joins MPM Capital’s Oncology Impact Fund Advisory Board
June 8, 2017
TCR2 Therapeutics to Debut Positive Solid Tumor Data on its Novel TRuC™ Engineered T Cell Platform at the World Preclinical Congress
June 6, 2017
Radius Presents Positive Data From A Fully Enrolled Ongoing Phase I Study for Investigational Drug Elacestrant (RAD1901) at the 2017 American Society of Clinical Oncology Annual Meeting (ASCO)
May 25, 2017
Amgen vet Patrick Baeuerle inspires a $45M round from A-list VCs for a next-gen I/O drug platform
May 25, 2017
Harpoon Therapeutics Announces Completion of $45M Series B Financing
May 23, 2017
MPM Portfolio Company True North Therapeutics Acquired by Bioverativ, Inc
Upfront payment of $400M plus assumed cash, with additional payments of up to $425M contingent on the achievement of future milestones
May 18, 2017
Syndax Shares Soar as Lead Drug Clears a Mid-Stage Cancer Drug Study Hurdle
May 4, 2017
Conatus Announces Exercise of License Option for Global Development and Commercialization of Emricasan Following Notice of Initiation of Phase 2b ENCORE-LF Clinical Trial in NASH Cirrhosis
May 3, 2017
Inside Perspectives on Cancer Immunotherapy: An Interview with MPM’s Christiana Bardon
April 28, 2017
FDA Approves MPM Portfolio Company Radius Health’s TYMLOS™ (abaloparatide)
Bone Building Agent for the Treatment of Postmenopausal Women with Osteoporosis at High Risk for Fracture
April 17, 2017
Meet One the Most Successful German Biotech Leaders Ever Read more about MPM’s Patrick Baeuerle
April 5, 2017
MPM Managing Director Chris Bardon Named a Top-40 Transformer
Top innovation gurus leading the biopharma industry's transformation are recognized by MM&M
April 4, 2017
MPM Portfolio Company Oncorus Nominated for 2017 NEVY Award as Hottest Early-Stage Startup Therapeutics
April 4, 2017
Syndax Pharmaceuticals Adds Biopharmaceutical Industry Leader Keith A. Katkin to Board of Directors
February 16, 2017
Rhythm Announces Completion of $41 Million Mezzanine Financing
— Proceeds to finance significant expansion of genetic obesity clinical trials —
February 7, 2017
Chris Varma, Co-founder and Former President and CEO of Blueprint Medicines, Joins MPM as Entrepreneur-in-Residence
January 11, 2017
MPM Portfolio Company Maverick Therapeutics and Takeda Announce Five-year Collaboration to Advance T-Cell Engagement Therapies
January 5, 2017
Accomplished Biotech Investor Ed Hurwitz Joins MPM as Managing Director
2016
December 19, 2016
MPM Portfolio Company, Astute Medical, Forms Strategic Partnership with Bio-Techne
December 19, 2016
Novartis Signs Exclusive Option, Collaboration and License Agreement with MPM Portfolio Company Conatus Pharmaceuticals Inc.
December 15, 2016
Oncorus®, Inc. Announces Additional Series A Financing Support From Astellas Venture Management LLC
December 13, 2016
Harpoon Therapeutics Appoints Gerald McMahon, Ph.D., as President and CEO
December 8, 2016
TCR2 Therapeutics Launches from Stealth Mode to Accelerate Development of Novel Cancer Immunotherapies
- $44.5M Series A Financing Led by MPM Capital and F2 Ventures -
December 2, 2016
Chris Bardon, MPM Managing Director, Comments to Bloomberg on New Approaches to Medical Philanthropy
Read full article – “A Few Billionaires Are Turning Medical Philanthropy on Its Head”
November 28, 2016
Epizyme Announces Fast Track Designation for Tazemetostat in DLBCL and Provides Tumor Program Update
November 21, 2016
Novartis Acquires MPM Portfolio Company Selexys Pharmaceuticals Corporation and SelG1 Antibody for Reduction of Pain Crises in Sickle Cell Disease
November 8, 2016
Harpoon Therapeutics Appoints Hans-Peter Gerber, PhD, As Chief Scientific Officer
November 7, 2016
Semma Therapeutics Announces Mark Fishman, M.D. Has Joined Its Board of Directors as Chairman
October 31, 2016
MPM Portfolio Company Epizyme Expands Clinical Programs through Cooperative Research and Development Agreements with the National Cancer Institute
October 27, 2016
Motus Therapeutics Inc., a Subsidiary of MPM Portfolio Company Rhythm Holding Co., LLC is to be Acquired by Allergan
Acquisition Announced Following Positive Results for Phase 2b Clinical Trial of Treatment for GI Disorders
October 13, 2016
True North Therapeutics Receives FDA Orphan Drug Designation for TNT009 for the Treatment of Autoimmune Hemolytic Anemia, Including Cold Agglutinin Disease (CAD)
October 11, 2016
Pacira Pharmaceuticals’ Kristen Williams is Honored as 1 of 15 “Fierce Women in Biopharma 2016”
Learn why Kristen stands out among women in the industry
September 22, 2016
iOmx Therapeutics Raises EUR 40 Million in Series A round
Company establishes top-tier investor base consisting of MPM Capital, Sofinnova Partners, Wellington Partners and Merck Ventures
September 19, 2016
Three MPM Portfolio Companies (Blade, Oncorus & Rhythm) Named to FierceBiotech’s “2016 Fierce 15” List
September 19, 2016
Radius Announces Publication of Additional Positive Results from the Phase 3 Active Trial of Osteoporosis Treatment
September 14, 2016
Tizona Therapeutics, Inc. Appoints George Golumbeski, Ph.D., to its Board of Directors
August 16, 2016
Osteoporosis, a Disease With Few Treatment Options, May Soon Have One More
Read coverage in NY Times and in Press Release
August 15, 2016
Aratana Secures Third FDA Approval
Animal pain drug expected to be available to veterinarians in the fall of 2016
August 11, 2016
Harvard Medical School Appoints MPM Medical and Scientific Advisory Co-Chair George Daley as New Dean
Read more in The Boston Globe
August 10, 2016
Iconic Therapeutics Announces Final Close of Series C Financing With Additional $10 Million Investment
August 1, 2016
Astellas and MPM Capital Launch DigiTx Partners
July 26, 2016
MPM Portfolio Company Blade Therapeutics Featured in the San Francisco Business Times
The July 19 article, “Taking it personally, cutting–edge biotech snags $45 million,” discusses the latest round of funding for Blade, a company focused on finding therapies for fibrotic disease, and MPM Co-Founder Luke Evnin’s personal commitment to the cause.
July 21, 2016
Rhythm Announces New England Journal of Medicine Publication of Setmelanotide Phase 2 Data for Treatment of POMC Deficiency Obesity
Significant weight loss with targeted treatment for patients with rare genetic defect in critical weight regulation pathway
July 20, 2016
Former Bluebird Bio (BLUE) CSO Takes the Reins at Oncorus; Startup Launches with $57 Million Series A
June 16, 2016
MPM Portfolio Company Semma Therapeutics Featured in Boston Globe
Boston-area hospitals have teamed up with the Harvard Stem Cell Institute and Semma Therapeutics to make personalized cell-based therapies and organize clinical trials.
June 2, 2016
Chris Bardon, Managing Director for the Oncology Impact Fund, on Bloomberg Capital Markets
Discussing Advances in Cancer Therapies as the 2016 ASCO Annual Meeting Gets Underway
May 27, 2016
TriNetX Enters into Collaboration with Celgene
Advance Clinical Trial Design and Research for Next-Generation Medicines Planned
May 18, 2016
Aratana Therapeutics Granted FDA Approval of ENTYCE®
First-of-its-Kind Ghrelin Mimetic
May 3, 2016
MPM Launches $471 Million Social Impact Oncology Fund
April 29, 2016
UBS Cancer Fund Shows Power of Impact Investing
A new oncology fund will finance academic research and access to cancer care in developing countries
April 28, 2016
UBS, MPM Seek Big ‘Impact’ in Cancer Drugs with $471M Fund
By Marie Powers, BioWorld Today, April 28, 2016
April 27, 2016
UBS Raises Record $471 Million for Oncology Impact Fund
BioSpace.com 4/27/2016
March 21, 2016
Aratana Therapeutics Granted First FDA Approval
Galliprant for the Control of Pain and Inflammation Associated with Osteoarthritis in Dogs
March 14, 2016
Chiasma Initiates Phase 3 Trial to Support European Registration of Octreotide Capsules for Patients with Acromegaly
March 8, 2016
Tizona Therapeutics, Inc., Completes $43 Million Series B Financing
March 6, 2016
Radius Health Submits New Drug Application to the U.S. Food and Drug Administration for Abaloparatide-SC for the Treatment of Postmenopausal Women with Osteoporosis
March 3, 2016
Nasdaq Welcomes Syndax Parmaceuticals, Inc. to The Nasdaq Stock Market
January 9, 2016
Iconic Therapeutics Closes Series C Financing
2015
October 15, 2015
Semma Therapeutics named FierceMedicalDevices’ 2015 Fierce 15
August 27, 2015
Syndax Enters Clinical Trial Collaboration in Cancer Immunotherapy Combining Entinostat and Atezolizumab
August 24, 2015
Syndax Raises $80 Million in Series C Financing
August 17, 2015
Rhythm Subsidiary Raises $40 Million in Oversubscribed Financing
Financing to advance Rhythm Metabolic, Inc.'s setmelanotide program for rare genetic disorders of obesity
August 15, 2015
Epizyme Appoints Robert Bazemore President and Chief Executive Officer
July 16, 2015
Chiasma, Inc. Prices Initial Public Offering of Common Stock
July 10, 2015
Taking Clinical Trials Out of the Dark Ages (Clinical Ink)
June 23, 2015
Briggs W. Morrison, M.D., CEO of Syndax, Appointed Key Strategic Advisor to MPM Capital
June 15, 2015
Chiasma Submits New Drug Application to U.S. FDA for Octreotide Capsules in Acromegaly
Submission based on positive results from Phase 3 clinical trial
June 1, 2015
K. Peter Hirth, PhD, Joins Iconic Therapeutics as Board Member and Senior Scientific Advisor
May 21, 2015
MPM Capital appoints Pablo J. Cagnoni, M.D., former Onyx Pharmaceuticals President, as Managing Director and CEO of MPM immunotherapy portfolio company Vesuvius
May 14, 2015
MPM closes $400 million fund
May 5, 2015
23andMe Launches the Lupus Research Study in Collaboration with Pfizer Inc.
With Lupus Awareness Month Underway, Study Aims to Build a 5,000-Patient Lupus Cohort to Advance Understanding of the Disease
April 22, 2015
Astellas Pharma and Potenza Therapeutics Partner to Build a Portfolio of Immuno-oncology Therapeutics
Exclusive Collaboration Includes Option for Astellas to Acquire Potenza
April 15, 2015
Novartis International Global Head M&A and Licensing Anthony Rosenberg to join as Managing Director, effective April 1, 2015
- To serve as strategic advisor and on MPM portfolio boards to build leading companies -
March 24, 2015
Biotech Startup to Fight Diabetes on the Cellular Front
Semma Therapeutics seeks to turn success in stem research lab into a way to encourage insulin production
March 24, 2015
Semma Therapeutics Announces $44 Million in Funding Led by MPM Capital to Develop Cell Therapy for Treating Type 1 Diabetes; Signs Agreement with Global Pharmaceutical Company
March 16, 2015
Ebb & Flow: Chiasma’s Private Decision
March 16, 2015
Chiasma Announces Mark Leuchtenberger as Chief Executive Officer
Proven Business Leader to Oversee Commercialization of Octreotide Capsules
March 12, 2015
23andMe to Create Therapeutics Group, Appoints Scientific Luminary, R&D Executive Richard Scheller, Ph.D. to Lead
Dr. Scheller Joins 23andMe’s Executive Leadership Team as Chief Science Officer and Head of Therapeutics
March 11, 2015
MPM Capital Announces Immuno-Oncology Pioneer Patrick Baeuerle to serve as Managing Director
-Top scientist and drug developer joins MPM senior team advancing breakthroughs and discoveries
March 10, 2015
Radius (RDUS) Announced Today That It Has Acquired The License To Develop And Market RAD1901 In Japan
Dinesh Purandare Hired (Former Sanofi (SAN.PA) Oncology Executive To The Position Of Senior Vice President (SVP) And Head Of Global Oncology At Radius )
February 27, 2015
Chiasma Announces Completion of $70 Million Series E Financing
February 27, 2015
Verastem Receives Orphan Drug Designation From FDA For VS-5584 In Mesothelioma
February 24, 2015
Chiasma Appoints David Stack as Chairman of the Board; John A. Scarlett, M.D. Joins Board of Directors
February 20, 2015
Syndax Says Immuno-oncology Discovery Happened Instead of an IPO
February 10, 2015
Chiasma Inc. Releases Newly Published Phase 3 Study Results
Show Positive Outcomes For Octreotide Capsules In People With Acromegaly, A Serious Hormonal Disorder
February 9, 2015
Radius, Celladon and Nevro Among Top IPOs in 2014
MPM has #1, 8 and 10 out of the top 14
January 1, 2015
Radius: The Top Performing IPO of 2014
Radius, which is developing treatments for osteoporosis, is up 364% since pricing its June 6 initial public offering at 8
2014
December 22, 2014
Radius Announces Positive Phase 3 Top-Line Results
December 15, 2014
For Venture Capital, Biotech is Where It’s Really At
August 4, 2014
Aratana Featured: Start-Ups Work on Biotech Drugs for Pets
June 17, 2014
True North snags $22M and sets course for the clinic with a rare disease drug
April 29, 2014
iPierian acquired by Bristol-Myers Squibb
Advances discovery strategy to pursue therapeutics for genetically defined diseases
April 16, 2014
Iconic Therapeutics Raises $20 Million to Advance Clinical Development of Wet AMD Program
William Greene, MD, Appointed Chief Executive Officer
April 14, 2014
Celladon Receives Breakthrough Therapy Designation from FDA
MYDICAR is First Gene Therapy Reported to Receive Breakthrough Designation from FDA’s Center for Biologics Evaluation and Research (CBER)
February 18, 2014
CoStim Pharmaceuticals, Inc. Acquired by Novartis
January 27, 2014
MPM Capital and Kleiner Perkins Caufield & Byers top the list of investors with the most 2013 IPOs
January 7, 2014
Epizyme and Celgene Advance EPZ-5676 DOT1L Inhibitor Clinical Program to Benefit Cancer Patients with Acute Leukemias, Achieving $25 Million Clinical Proof of Concept Milestone
- 2023
- 2022
- 2021
- 2020
- 2019
- 2018
- 2017
- 2016
- 2015
- 2014
X
X
X
Please click here for all funds: Investor Login
X